The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.
 
Lin-Quan Tang
No Relationships to Disclose
 
Li-Ting Liu
No Relationships to Disclose
 
Huai Liu
No Relationships to Disclose
 
Ying Huang
No Relationships to Disclose
 
Feng Jin
No Relationships to Disclose
 
Si-Yi Xie
No Relationships to Disclose
 
Yuan-Yuan Li
No Relationships to Disclose
 
Shan-Shan Guo
No Relationships to Disclose
 
Xiao-Yun Li
No Relationships to Disclose
 
Dong-Ping Chen
No Relationships to Disclose
 
Bin Qi
No Relationships to Disclose
 
Jin-Hao Yang
No Relationships to Disclose
 
Xue-Song Sun
No Relationships to Disclose
 
Zhen-Chong Yang
No Relationships to Disclose
 
Sai-Lan Liu
No Relationships to Disclose
 
Dong-Hua Luo
No Relationships to Disclose
 
Ji-Bin Li
No Relationships to Disclose
 
Qiu-Yan Chen
No Relationships to Disclose
 
Rui Sun
No Relationships to Disclose
 
Hai-Qiang Mai
No Relationships to Disclose
 
A. Dimitrios Dimitrios Colevas
Consulting or Advisory Role - Alpha BioCom; Beigene; ClearView Healthcare Partners; Deallus; Gilead Sciences; leidos biomedical research
Research Funding - Abbvie; AstraZeneca; Atara Biotherapeutics; BioNtech; BMS; CUE Biopharma; Cullinan Oncology; Exelixis; Experimental Therapeutics Clinical Trials Network (ETCTN); Forty Seven; Innate Pharma; Merck; NIH/NCI; NRG Oncology; Tessa Therapeutics